Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn:
* About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Has histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations
Has documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy and platinum-based chemotherapy
Provides archival tumor tissue sample of a tumor lesion not previously irradiated
Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
Merck Sharp & Dohme LLC
Lead sponsor
Daiichi Sankyo
Collaborator